Harvey AI vs Causaly (2026)

Harvey AI

by Harvey

Causaly

by Causaly

Pros

• ✓Harvey Agents execute complex legal work end-to-end: from contract analysis and due diligence through document drafting and research, agents create plans, execute across connected systems, and deliver results without step-by-step attorney direction. This represents the highest autonomous capability of any legal AI platform in the index.
• ✓$1.22B raised from Sequoia, Andreessen Horowitz, Kleiner Perkins, GIC, and OpenAI at $11B valuation with $190M ARR. This is the strongest funding, revenue, and institutional backing of any legal AI company, with named enterprise clients including Dentons, KKR, Bridgewater, PwC, Deutsche Telekom, and Procter and Gamble alongside the majority of top global law firms.
• ✓Action-level DMS integration creates, reads, and updates documents in iManage, NetDocuments, and SharePoint with research grounded in Westlaw and LexisNexis. Harvey participates in the full document lifecycle of legal matters rather than operating as a standalone research tool.

Limitations

• ⚠Enterprise-only pricing with no self-serve option: typical annual contracts run six figures, making Harvey inaccessible for solo practitioners and small firms. Spellbook (custom pricing, demo-gated) and Consensus ({{consensus.starting_price}}) provide accessible entry points for basic legal AI capabilities.
• ⚠Deployment requires 4 to 12 weeks including firm security review, custom model configuration, DMS integration, and attorney training. This is not a tool teams can activate and evaluate quickly, creating friction for firms weighing AI adoption against faster-deploying alternatives.
• ⚠Review volume significantly understates actual adoption: 2 G2 reviews and 6 Gartner ratings as of July 2026 despite 142,000+ active professionals. Procurement teams relying on review platforms for vendor evaluation will find thin public evidence relative to deployment scale.

Pros

• ✓Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
• ✓Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
• ✓Agentic AI agents purpose-built for pharmaceutical R&D use cases including target identification, drug repositioning, mechanism of action investigation, and safety assessment produce outputs with traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

• ⚠Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
• ⚠Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
• ⚠Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/month) or ChatGPT Deep Research ($20/month) substantially more cost-effective outside pharma R&D workflows.